ResearcherHarvard UniversityActive in the last 2 years

Cho‐Han Chiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5757-6161; OpenAlex author ID A5007502940. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 4

Semaglutide and Risk of Pancreatic Cancer: A Meta-Analysis of Randomised Trials. Co-author DOI 10.1111/dom.70980 ↗
The Efficacy of Cationic Amphiphilic Antihistamines on Outcomes of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12029-023-00969-6 ↗
Pancreatic cancer mortality trends in the United States: how much have we moved the needle? Co-author DOI 10.21037/jgo-24-213 ↗
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adeno… Co-author DOI 10.1097/mpa.0000000000002125 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Brian Shiian Chen · 2 shared papers, 2022–2024 · strength 0.39
- Paper The Efficacy of Cationic Amphiphilic Antihistamines on Outcomes of Patients with Pancreatic Ductal Adenocarcinoma. DOI 10.1007/s12029-023-00969-6 ↗
- Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125 ↗
Cheng‐Ming Peng · 2 shared papers, 2022–2024 · strength 0.39
- Paper The Efficacy of Cationic Amphiphilic Antihistamines on Outcomes of Patients with Pancreatic Ductal Adenocarcinoma. DOI 10.1007/s12029-023-00969-6 ↗
- Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125 ↗
Cho‐Hung Chiang · 1 shared paper, 2026 · strength 0.36
- Paper Semaglutide and Risk of Pancreatic Cancer: A Meta-Analysis of Randomised Trials. DOI 10.1111/dom.70980 ↗
Zhi Ven Fong · 1 shared paper, 2024 · strength 0.24
- Paper Pancreatic cancer mortality trends in the United States: how much have we moved the needle? DOI 10.21037/jgo-24-213 ↗
Nabil Wasif · 1 shared paper, 2024 · strength 0.24
- Paper Pancreatic cancer mortality trends in the United States: how much have we moved the needle? DOI 10.21037/jgo-24-213 ↗
Chee‐Chee Stucky · 1 shared paper, 2024 · strength 0.24
- Paper Pancreatic cancer mortality trends in the United States: how much have we moved the needle? DOI 10.21037/jgo-24-213 ↗
Jia Yi Tan · 1 shared paper, 2024 · strength 0.24
- Paper Pancreatic cancer mortality trends in the United States: how much have we moved the needle? DOI 10.21037/jgo-24-213 ↗
Kevin Sheng‐Kai Ma · 1 shared paper, 2022 · strength 0.15
- Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125 ↗
Yu‐Ze Luan · 1 shared paper, 2022 · strength 0.15
- Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.